Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma

Sorafenib resistance is one of the major obstacles towards achieving a better outcome in patients with advanced hepatocellular carcinoma (HCC), in which aberrant activation of the hepatocyte growth factor (HGF)/mesenchymal‐epithelial transition pathway is frequently observed. Here, we report that HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Weibo, Yang, Junsheng, Zhang, Yue, Cai, Huihua, Chen, Xuemin, Sun, Donglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356182/
https://www.ncbi.nlm.nih.gov/pubmed/30761258
http://dx.doi.org/10.1002/2211-5463.12578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356182/
https://www.ncbi.nlm.nih.gov/pubmed/30761258
http://dx.doi.org/10.1002/2211-5463.12578

Ejemplares similares